ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,781,000 | +70.5% | 260,000 | +101.4% | 0.50% | +45.2% |
| Q1 2023 | $1,044,419 | -51.4% | 129,100 | -5.4% | 0.34% | -42.4% |
| Q3 2022 | $2,147,000 | +53.8% | 136,434 | +36.4% | 0.60% | +1.9% |
| Q2 2022 | $1,396,000 | -19.0% | 100,000 | 0.0% | 0.59% | +113.0% |
| Q1 2022 | $1,724,000 | -70.4% | 100,000 | -75.0% | 0.28% | -86.9% |
| Q4 2021 | $5,816,000 | -7.7% | 400,000 | +14.3% | 2.11% | +32.7% |
| Q3 2021 | $6,300,000 | +30.5% | 350,000 | +27.3% | 1.59% | -8.0% |
| Q2 2021 | $4,829,000 | -13.8% | 275,000 | +23.7% | 1.73% | -9.1% |
| Q1 2021 | $5,601,000 | – | 222,267 | – | 1.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |